Extraordinary Cases in VTE

Slides:



Advertisements
Similar presentations
Neue Antikoagulantien bei spontaner und Tumor-assoziierter VTE Paul Kyrle Univ. Klinik f. Innere Medizin I AKH/Medizinische Universität Wien.
Advertisements

Warfarin Efficacy in Cancer Patients on Long-term Anticoagulation Neha Doshi, PharmD Candidate LeAnn B. Norris, PharmD, BCPS P. Brandon Bookstaver, PharmD,
Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer Agnes Y. Y. Lee, MD, MSc; Pieter W. Kamphuisen, MD,
Addressing the Challenges in Primary and Secondary Stroke Prevention
Evolving Paradigms in Recurrent/Metastatic SCCHN
Major Depressive Disorder: Latest Clinical Update
Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.
NOACs for Cancer-Associated Thrombosis:
Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.
NOACs In Long-term VTE Treatment: A State Of The Art Review
Long-Term Treatment of VTE: Case Studies
US Guidelines US Guidelines Low-risk Patients.
Thrombosis, Cancer, and NOACs
Access to NOAC Therapy:
The Nurse View.
Emergency Management of NOAC Bleeding
A New Era for NOACs:.
Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?
Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.
Anticoagulation Highlights From the American Heart Association Meeting 2017.
Up to Date on Which NOAC for Which Patient
Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.
The Nurse View: Updates in the Management of Metastatic Colorectal Cancer.
Surveying the Safety of NOACs in the Real World
Selecting NOACs for High-Risk Patients
Panelists. Secondary Prevention of Acute Ischemic Stroke: Can We Improve Outcomes?
New Oral Anticoagulants and VTE Management
Real-World Safety of NOACs: What Do We Know Today?
VTE Treatment Conventional Approach
Efficacy and Safety of Edoxaban in Patients With AF and HF
Using CDK4/6 Inhibitors to Manage HR-Positive Metastatic Breast Cancer
Access to NOAC Therapy:
Learning Objectives Classification of VTE Goals of VTE Treatment.
A Better Solution For Cancer Patients With VTE?
VTE in Cancer.
Oral Anticoagulation in AF
Real-World Evidence in VTE
Extending Treatment for Thrombosis: What’s the Right Choice?
Aspirin in Cardioprevention:
Practical Considerations to Extend Treatment for VTE
Atrial Fibrillation.
Extraordinary Cases of VTE Prevention in Patients With Cancer
Treatment of Thromboembolic Disease The Need for Multiple Perspectives
Using Heart Rate as a Biomarker in Clinical Practice.
Anticoagulation and Thrombosis Management
Aspirin and Cardioprevention in 2018
Trials and Tribulations in VTE: How Do Real-World Data Fit In?
Long-Term Treatment of VTE: Case Studies
Factor Xa Inhibitors in PAD
CAD/PAD in Primary Care
A Time for Change for Managing Patients With VTE Who Have Cancer
Cancer-Associated Thrombosis
Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?
Managing Pulmonary Embolism Posthospital Discharge
NOAC Studies in VTE AF Studies Superior Outcomes.
Program Goals Background: Anticoagulation in Patients With VTE.
NOACs in CAD.
Factor Xa Inhibitors in Coronary Artery Disease
Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in.
An Unmet Need.
Disease Burden of VTE Phases of VTE Treatment.
5 Good Minutes on Atrial Fibrillation-related Stroke
Selecting Treatment Approaches in Hemophilia
At the Crossroads of Coagulation
VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.
New Concepts in Cancer-Associated Thrombosis
Treatment algorithm. Treatment algorithm. (A) Suggested treatment algorithm for symptomatic and incidental DVT or PE in cancer patients. (B) Suggested.
Antithrombotic Therapy in AF Patients Undergoing PCI
What's New in NOACs in AF?.
Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?
Presentation transcript:

Extraordinary Cases in VTE

Patient Case

Guideline Recommendations Treatment and Secondary Prophylaxis of Cancer-Associated VTE

2018 NCCN Guidelines for Cancer-Associated VTE

Patient Characteristics to Consider when Selecting NOAC vs LMWH

LMWH and Chemotherapy-Induced Thrombocytopenia

Hokusai-VTE Cancer − Study Design

HOKUSAI-VTE Cancer Primary Outcome First Recurrent VTE or Major Bleeding Event

Drop in Platelet Count Insights from the Hokusai-VTE Cancer Trial

SELECT-D Dalteparin vs Rivaroxaban in Patients with Cancer

Sites of Major Bleeding

Hokusai-VTE Cancer Secondary Outcomes

GI Cancer and Major Bleeding

US Prescription Patterns for Cancer-Associated VTE

Potential Anticancer and NOAC Drug Interactions

Take-Home Messages

Abbreviations

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.